Evidence map›Paper›PMID 33726828›Full record

ArticleTrials2021

Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial.

Trishul Siddharthan, Suzanne L Pollard, Peter Jackson, Nicole M Robertson, Adaeze C Wosu, Nihaal Rahman, Roma Padalkar, Isaac Sekitoleko, Esther Namazzi, Patricia Alupo and 7 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03984188 (Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03984188 phase3completednot on this map

Effectiveness of Low-Dose Theophylline for the Management of Biomass-Associated COPD

TypeinterventionalSponsorUniversity of MiamiRan2021 to 2023Enrolled100ConditionsCOPD, COPD Exacerbation, COPD Exacerbation Acute, Pollution Related Respiratory DisorderArmsTheophylline ER, Placebo oral tablet, Standard of Care Treatment
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 3 countries.

Trishul SiddharthanDivision of Pulmonary and Critical Care, University of Miami, School of Medicine, Johns Hopkins University, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA. tsiddhar@miami.edu.ORCID http://orcid.org/0000-0001-9914-1839
Suzanne L PollardDivision of Pulmonary and Critical Care, University of Miami, School of Medicine, Johns Hopkins University, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA.
Peter JacksonDivision of Pulmonary and Critical Care, Virginia Commonwealth University, Richmond, USA.
Nicole M RobertsonDivision of Pulmonary and Critical Care, University of Miami, School of Medicine, Johns Hopkins University, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA.
Adaeze C WosuCenter for Global Non-Communicable Diseases, Johns Hopkins University, Baltimore, USA.
Nihaal RahmanDivision of Pulmonary and Critical Care, University of Miami, School of Medicine, Johns Hopkins University, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA.
Roma PadalkarDivision of Pulmonary and Critical Care, University of Miami, School of Medicine, Johns Hopkins University, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA.
Isaac SekitolekoMakerere University Lung Institute, Makerere College of Health Sciences, Kampala, Uganda.
Esther NamazziMakerere University Lung Institute, Makerere College of Health Sciences, Kampala, Uganda.
Patricia AlupoMakerere University Lung Institute, Makerere College of Health Sciences, Kampala, Uganda.
John R HurstUCL Respiratory, University College London, London, UK.
Robert KalyesubulaDepartment of Physiology, Makerere College of Health Sciences, Kampala, Uganda.
David DowdyDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, USA.
Robert WiseDivision of Pulmonary and Critical Care, University of Miami, School of Medicine, Johns Hopkins University, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA.
Peter J BarnesNational Health and Lung Institute, Imperial College, London, UK.
William CheckleyDivision of Pulmonary and Critical Care, University of Miami, School of Medicine, Johns Hopkins University, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA.
Bruce KirengaMakerere University Lung Institute, Makerere College of Health Sciences, Kampala, Uganda.
Johns Hopkins University · USMakerere University · UGImperial College London · GBUniversity College London · GBVirginia Commonwealth University · US

Funding

Effectiveness of Low-dose Theophylline for the Management of Biomass-associated COPD in PeruK23HL146946 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SIDDHARTHAN, TRISHUL · 2019 to 2023
$985k
NHLBI NIH HHS K23 HL146946NHLBI NIH HHS K23HL146946
6 · The paper itself

Abstract

backgroundCOPD is a leading cause of death globally, with the majority of morbidity and mortality occurring in low- and middle-income country (LMIC) settings. While tobacco-smoke exposure is the most important risk factor for COPD in high-income settings, household air pollution from biomass smoke combustion is a leading risk factor for COPD in LMICs. Despite the high burden of biomass smoke-related COPD, few studies have evaluated the efficacy of pharmacotherapy in this context. Currently recommended inhaler-based therapy for COPD is neither available nor affordable in most resource-limited settings. Low-dose theophylline is an oral, once-a-day therapy, long used in high-income countries (HICs), which has been proposed for the management of COPD in LMICs in the absence of inhaled steroids and/or bronchodilators. The Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD) trial investigates the clinical efficacy and cost-effectiveness of low-dose theophylline for the management of biomass-related COPD in a low-income setting.

methodsLODOT-BCOPD is a randomized, double-blind, placebo-controlled trial to test the efficacy of low-dose theophylline in improving respiratory symptoms in 110 participants with moderate to severe COPD in Central Uganda. The inclusion criteria are as follows: (1) age 40 to 80 years, (2) full-time resident of the study area, (3) daily biomass exposure, (4) post-bronchodilator FEV

trial registrationClinicalTrials.gov  NCT03984188 . Registered on June 12, 2019 TRIAL ACRONYM: Low-dose Theophylline for the Management of Biomass-Associated COPD (LODOT-BCOPD).

Indexed as

Pulmonary Disease, Chronic ObstructiveTheophyllineAdultAgedAged, 80 and overBiomassBronchodilator AgentsDouble-Blind MethodHumansMiddle AgedQuality of LifeRandomized Controlled Trials as TopicUgandaBronchodilator AgentsTheophyllineBiomassCOPDTheophylline

Identifiers

PMID33726828
PMCPMC7962083
OpenAlexW3120498006

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.